SEC Tracker
Get the app

Dyne Therapeutics DYN

ForDyne (Affiliate) plans to sell 807,295 DYN shares, about $14.3M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Mar 9, 2026
  2. Broker: UBS Financial Services Inc.
  3. Shares acquired by: IPO Conversion of Shares
  4. 10b5-1 plan adopted: Nov 11, 2025

All of ForDyne's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Dyne Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Akebia Therapeutics AKBA public float $946M, Jun 30, 2025
  2. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  3. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  4. Neogen NEOG public float $972M, Nov 30, 2025
  5. Ardelyx ARDX public float $924M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.